Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

Title: OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic anti-tumor effect in combination with pembrolizumab

Abstract number: 5946 / Poster number: 5946/7

Title: Globo H-targeted CAR T cell cancer immunotherapy

Abstract number: 4084 / Poster Number: 4084/3

Company Overview

Management Team

ESG

Pipeline

News

Investor Overview

Careers

Contact

Date Privacy Notice

© 2020 OBI Pharma.Web Development by 展躍設計